Key Points
- Immunome insider Jack Higgins sold 13,200 shares for approximately $334,224 at an average price of $25.32 under a pre-arranged Rule 10b5-1 trading plan, reducing his stake by 16.87%.
- Immunome shares opened at $23.95, with a $2.72 billion market capitalization, a 52-week range of $8.93 to $30.06, and a beta of 2.13.
- Analysts maintain a generally positive outlook, with 12 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $34.64; however, the company recently missed quarterly EPS estimates.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) insider Jack Higgins sold 13,200 shares of Immunome stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the sale, the insider owned 65,050 shares in the company, valued at $1,647,066. This trade represents a 16.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Immunome Stock Performance
Immunome stock opened at $23.95 on Wednesday. The company has a market capitalization of $2.72 billion, a P/E ratio of -9.47 and a beta of 2.13. Immunome, Inc. has a fifty-two week low of $8.93 and a fifty-two week high of $30.06. The stock has a 50-day simple moving average of $25.33 and a 200-day simple moving average of $22.74.
Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). As a group, analysts forecast that Immunome, Inc. will post -2.38 earnings per share for the current year.
Wall Street Analysts Forecast Growth
IMNM has been the topic of a number of research reports. Barclays started coverage on shares of Immunome in a research report on Thursday, May 28th. They set an "overweight" rating and a $36.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Immunome in a research report on Thursday, September 10th. Wedbush increased their price target on shares of Immunome from $31.00 to $35.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Citigroup reiterated a "buy" rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a research note on Friday, July 17th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Immunome presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.64.
Get Our Latest Analysis on Immunome
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new stake in shares of Immunome in the first quarter valued at approximately $1,507,000. California State Teachers Retirement System raised its position in Immunome by 66.3% in the first quarter. California State Teachers Retirement System now owns 111,444 shares of the company's stock worth $2,437,000 after acquiring an additional 44,432 shares in the last quarter. Bank of America Corp DE raised its position in Immunome by 285.6% in the first quarter. Bank of America Corp DE now owns 781,607 shares of the company's stock worth $17,094,000 after acquiring an additional 578,890 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in Immunome in the first quarter valued at $1,310,000. Finally, Profund Advisors LLC lifted its holdings in Immunome by 121.7% in the fourth quarter. Profund Advisors LLC now owns 42,700 shares of the company's stock valued at $917,000 after acquiring an additional 23,440 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.
Immunome's activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
